Scleroderma renal crisis as the sole presenting feature of systemic sclerosis in a postpartum woman

Systemic sclerosis is a chronic autoimmune disorder characterized by multiorgan involvement, most notably of the skin through fibrosis and vasculopathy. One of its most feared complications requiring rapid intervention is scleroderma renal crisis, as it can be fatal in the absence of prompt treatment. A 34-year old woman presents with a history of acute renal failure and malignant hypertension occurring one month postpartum and no other scleroderma feature in the following 5 years. Eventually, skin, heart and lung involvement is observed, positive anti-ARN III polymerase antibodies and suggestive capillaroscopic findings. Immunosuppressive therapy with mycophenolate mofetil is initiated and later switched to off-label Rituximab, with significant improvement of disease manifestations. Regular patient monitoring for novel symptom occurrence and appropriate treatment adjustment is essential for optimal management of scleroderma.

[1]  Isac Davidson Santiago Fernandes Pimenta,et al.  Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis , 2021, Advances in Rheumatology.

[2]  V. Vilela,et al.  Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. , 2016, Revista Brasileira de Reumatologia.

[3]  D. Furst,et al.  Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[4]  S. Lakshminarayanan,et al.  Scleroderma renal crisis as an initial presentation of systemic sclerosis: a case report and review of the literature. , 2015, Clinical and experimental rheumatology.

[5]  S. Bhavsar,et al.  Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[6]  C. Denton,et al.  320. The Prognosis of Scleroderma Renal Crisis in RNA-Polymerase III Antibody-Positive Compared to Rna-Polymerase III Antibody-Negative Patients , 2014 .

[7]  D. Huscher,et al.  Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group , 2014, Annals of the rheumatic diseases.

[8]  L. Punzi,et al.  Prognosis of scleroderma renal crisis: a long-term observational study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  J. Bijlsma,et al.  Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. , 2013, Clinical and experimental rheumatology.